Drug intelligence / Profile preview

BI 163538

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 163538 is an investigational small molecule drug developed by Boehringer Ingelheim. It is currently in phase I clinical trials as an oral solution for an undisclosed indication. The specific mechanism of action and therapeutic target have not been publicly disclosed. No additional information regarding its pharmacological class or intended disease area has been released.

Targets

GPR119 (Glucose-dependent insulinotropic receptor)

Beyond the preview

Go deeper on BI 163538.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 163538.

Explore the full profile